Communiqués Jasper Therapeutics, Inc.

Actions

JSPR

US4718712023

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 15/07/2024			Varia. 5j.	Varia. 1 janv.
19,92 ^USD	+4,29 %		-5,68 %	+152,47 %

19/06	Jasper Therapeutics, Inc. annonce des changements au sein de son conseil d'administration	CI
14/06	Jasper Therapeutics, Inc. présente les données de l'étude préclinique sur le briquilimab au congrès hybride de l'EHA 2024	CI

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Jasper Therapeutics Announces Appointment of Svetlana Lucas Ph.D., to its Board of Directors	19/06	AQ
Jasper Therapeutics to Present at the Oppenheimer Novel Targets in Immunology Summit	17/06	AQ
Jasper Therapeutics Presents Data from Preclinical Briquilimab Study at the 2024 EHA Hybrid Congress	17/06	AQ
Jasper Therapeutics Presents Data from Preclinical Briquilimab Study at the 2024 EHA Hybrid Congress	14/06	AQ
Jasper Therapeutics to Present Data on Briquilimab in Mast Cell Driven Diseases at the EAACI Congress 2024	31/05	AQ
Jasper Therapeutics to Present at the Jefferies Global Healthcare Conference	29/05	AQ
Jasper Therapeutics : Corporate Presentation May 2024	20/05	PU
Jasper Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Developments	14/05	AQ
Jasper Therapeutics : Corporate Presentation May 2024	13/05	PU
Jasper Therapeutics Announces Briquilimab Development Program in Asthma	13/05	AQ
Jasper Therapeutics to Present at Upcoming Investor Conferences in May	07/05	AQ
Jasper Therapeutics : Corporate Presentation April 2024	16/04	PU
Jasper Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference	02/04	AQ
Jasper Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference	21/03	AQ
Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible Urticaria	19/03	AQ
New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia	15/03	AQ
Jasper Therapeutics Reports Fiscal 2023 Financial Results and Recent Corporate Developments	04/03	AQ
Jasper Therapeutics : Corporate Presentation March 2024	04/03	PU
Jasper Therapeutics to Present at the 43rd Annual TD Cowen Healthcare Conference	26/02	AQ
Jasper Therapeutics Presents Data from Preclinical Briquilimab Studies at the American Academy of Allergy, Asthma, and Immunology Annual Meeting	26/02	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Jasper Therapeutics, Inc.

Actions

JSPR

US4718712023

Communiqués

Filtres